Baird Medical Investment Holdings Limited filed a Form 6-K on November 5, 2026, disclosing that it received a Nasdaq minimum bid price deficiency notification on November 2, 2026, and that it has until May 3, 2027 to regain compliance.

Key Highlights

  • Deficiency notice received: Baird Medical received a letter from the Nasdaq Listings Qualifications Department on November 2, 2026, stating its ordinary shares had closed below $1.00 for 30 consecutive business days.
  • Listing rule cited: The notification references Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.
  • Compliance deadline: The company has 180 calendar days, until May 3, 2027, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A).
  • Trading continues: According to the filing, "the shares will continue to trade uninterrupted under the symbol 'BDMD.'"
  • Potential extension: If compliance is not achieved by May 3, 2027, the company may be eligible for an additional 180 calendar day grace period, subject to meeting specified conditions.
  • Share price volatility disclosure: On November 4, 2026, the company also issued a separate press release regarding recent volatility in the market price of its ordinary shares.

Baird Medical Discloses Nasdaq Bid Price Deficiency and 180-Day Cure Period

According to the Form 6-K filed with the SEC on November 5, 2026, Baird Medical Investment Holdings Limited (NASDAQ:BDMD) received a letter dated November 2, 2026, from the Nasdaq Listings Qualifications Department. The letter notified the company that the minimum closing bid price per share of its ordinary shares, which carry a par value of US$0.0001 each, had been below $1.00 for a period of 30 consecutive business days, placing the company out of compliance with Nasdaq Listing Rule 5550(a)(2).

The filing states that "the Nasdaq notification letter does not result in the immediate delisting of the Company's Ordinary Shares." The company disclosed that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), it has a compliance period of 180 calendar days, running until May 3, 2027, to regain compliance. Compliance can be achieved if the closing bid price of the ordinary shares is at least $1.00 for a minimum of ten consecutive business days at any point during that period, upon which Nasdaq would provide written confirmation that the matter is closed.

The filing further discloses that if the company does not regain compliance by May 3, 2027, it may qualify for an additional 180 calendar day grace period. To be eligible, the company would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except the bid price requirement, and would need to provide written notice of its intention to cure the deficiency along with a proposed compliance plan. Separately, the company also disclosed that on November 4, 2026, it issued a press release addressing recent volatility in the market price of its ordinary shares.

What Was Disclosed

Baird Medical Investment Holdings Limited reported receiving a Nasdaq bid price deficiency notice on November 2, 2026, citing a closing price below $1.00 for 30 consecutive business days. The company has until May 3, 2027 to regain compliance, with a possible additional 180-day extension period available thereafter.